🔎 Trials Near Me

Akèy › Kansè kolon › Ohio › Columbus

Etid klinik pou Kansè kolon nan Columbus, OH

11 etid pou Kansè kolon ap chèche patisipan nan sit nan ak bò kote Columbus (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.

Tèks ofisyèl etid la (Anglè)

Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →

A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors

Ap rekriteFaz 1
  • ALX Center 10, Columbus
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07085091

A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

Ap rekriteFaz 3
  • Ohio State University-Arthur G James Comprehensive Cancer Center, Columbus
  • Ohio Health, Columbus
  • Zangmeister Center, Columbus
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT07284849

Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps

Ap rekrite
  • Ohio State University Comprehensive Cancer Center, Columbus
Laj 45 a 70 · Tout sèks · Mizajou Sep 2, 2026 · NCT05080673

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

Ap rekriteFaz 2/3
  • Ohio State University Comprehensive Cancer Center, Columbus
  • Mount Carmel East Hospital, Columbus
  • The Mark H Zangmeister Center, Columbus
  • ak 6 plis
Laj 18 ak plis · Tout sèks · Mizajou Sep 2, 2026 · NCT05174169

Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

Ap rekriteFaz 1
  • Xencor Investigative Site, Columbus
Laj 18 ak plis · Tout sèks · Mizajou Aug 3, 2026 · NCT05433142

Strategies for Optimizing a Mailed FIT Program in Appalachia

Ap rekrite
  • Ohio State University Comprehensive Cancer Center, Columbus
Laj 45 a 74 · Tout sèks · Mizajou Jul 9, 2026 · NCT07173985

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

Ap rekriteFaz 1/2
  • The Ohio State University Comprehensive Cancer Center, Columbus
Laj 18 ak plis · Tout sèks · Mizajou Jun 12, 2026 · NCT06051695

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Ap rekriteFaz 1/2
  • The Ohio State University Wexner Medical Center, Columbus
Laj 12 ak plis · Tout sèks · Mizajou May 27, 2026 · NCT03093116

Designing a Dyad-Based mHealth Intervention to Improve Adherence to Lifestyle Recommendations in Colorectal Cancer Survivors and Their Family Caregivers

Ap rekriteVolontè an sante akeyi
  • Ohio State University Comprehensive Cancer Center, Columbus
Laj 18 ak plis · Tout sèks · Mizajou Apr 9, 2026 · NCT06746012

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Ap rekriteEtid obsèvasyon
  • Massive Bio SYNERGY-AI site, Columbus
Tout laj · Tout sèks · Mizajou Oct 28, 2025 · NCT03452774

A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

Ap rekriteFaz 1/2
  • The Ohio State University, Columbus
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2025 · NCT06682793

Etid Kansè kolon nan lòt vil

Lòt etid nan Columbus

Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.